Tumor-infiltrating lymphocytes (TILs) in breast cancer are a key representative of the tumor immune microenvironment and have been shown to provide prognostic and predictive biomarkers. The extent of lymphocytic infiltration in tumor tissues can be assessed by evaluating hematoxylin and eosin (H&E)-stained tumor sections. We investigated tissue microarrays of 31 invasive breast cancer patients, looking at quantity and topological distribution of CD3+, CD8+, CD20+, Ki67+, FoxP3+ TILs and CD3+/FoxP3+, CD8+/FoxP3+ cell ratios. We separately evaluated TILs at the invasive edge and at the center of the tumor, to find any clinical implications of tumor heterogeneity. No statistically significant difference was found in quantity and distribution o...
In breast cancer (BC), the development of cancer immunotherapy including immune checkpoint inhibitor...
BACKGROUND: Clinical relevance of tumor infiltrating lymphocytes (TILs) in breast cancer is controve...
With the advance in personalized therapeutic strategies in patients with breast cancer, there is an ...
Tumor-infiltrating lymphocytes (TILs) in breast cancer are a key representative of the tumor immune ...
Tumor-infiltrating lymphocytes (TILs) in breast cancer are a key representative of the tumor immune ...
Tumor-infiltrating lymphocytes (TILs) in breast cancer are a key representative of the tumor immune ...
Background: Tumour-infiltrating lymphocytes (TILs) in breast cancer (BC) confer prognostic and predi...
Background: Tumour-infiltrating lymphocytes (TILs) in breast cancer (BC) confer prognostic and predi...
Background: Tumour-infiltrating lymphocytes (TILs) in breast cancer (BC) confer prognostic and predi...
Background: Tumour-infiltrating lymphocytes (TILs) in breast cancer (BC) confer prognostic and predi...
Background: Tumour-infiltrating lymphocytes (TILs) in breast cancer (BC) confer prognostic and predi...
Tumor infiltrating lymphocytes (TILs) are a significant component of the tumor microenvironment [1]....
Tumor-infiltrating lymphocytes (TILs) have been established as a robust prognostic biomarker in brea...
Breast cancer is the leading cause of cancer death in women worldwide with high incidence rate. Inva...
In breast cancer (BC), the development of cancer immunotherapy including immune checkpoint inhibitor...
In breast cancer (BC), the development of cancer immunotherapy including immune checkpoint inhibitor...
BACKGROUND: Clinical relevance of tumor infiltrating lymphocytes (TILs) in breast cancer is controve...
With the advance in personalized therapeutic strategies in patients with breast cancer, there is an ...
Tumor-infiltrating lymphocytes (TILs) in breast cancer are a key representative of the tumor immune ...
Tumor-infiltrating lymphocytes (TILs) in breast cancer are a key representative of the tumor immune ...
Tumor-infiltrating lymphocytes (TILs) in breast cancer are a key representative of the tumor immune ...
Background: Tumour-infiltrating lymphocytes (TILs) in breast cancer (BC) confer prognostic and predi...
Background: Tumour-infiltrating lymphocytes (TILs) in breast cancer (BC) confer prognostic and predi...
Background: Tumour-infiltrating lymphocytes (TILs) in breast cancer (BC) confer prognostic and predi...
Background: Tumour-infiltrating lymphocytes (TILs) in breast cancer (BC) confer prognostic and predi...
Background: Tumour-infiltrating lymphocytes (TILs) in breast cancer (BC) confer prognostic and predi...
Tumor infiltrating lymphocytes (TILs) are a significant component of the tumor microenvironment [1]....
Tumor-infiltrating lymphocytes (TILs) have been established as a robust prognostic biomarker in brea...
Breast cancer is the leading cause of cancer death in women worldwide with high incidence rate. Inva...
In breast cancer (BC), the development of cancer immunotherapy including immune checkpoint inhibitor...
In breast cancer (BC), the development of cancer immunotherapy including immune checkpoint inhibitor...
BACKGROUND: Clinical relevance of tumor infiltrating lymphocytes (TILs) in breast cancer is controve...
With the advance in personalized therapeutic strategies in patients with breast cancer, there is an ...